225 related articles for article (PubMed ID: 25181626)
21. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
22. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
23. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
24. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
25. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients.
Huo J; Hu J; Liu G; Cui Y; Ju Y
Arch Gynecol Obstet; 2017 Feb; 295(2):459-465. PubMed ID: 27975129
[TBL] [Abstract][Full Text] [Related]
26. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
[TBL] [Abstract][Full Text] [Related]
28. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
29. Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy.
Bozas G; Terpos E; Gika D; Karadimou A; Dimopoulos MA; Bamias A
Int J Gynecol Cancer; 2010 Feb; 20(2):248-54. PubMed ID: 20134268
[TBL] [Abstract][Full Text] [Related]
30. Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
Fukuda T; Imai K; Yamauchi M; Teramae M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T
Eur J Gynaecol Oncol; 2015; 36(1):49-53. PubMed ID: 25872334
[TBL] [Abstract][Full Text] [Related]
31. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
Yang ZJ; Zhao BB; Li L
J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
[TBL] [Abstract][Full Text] [Related]
32. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
33. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
34. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
35. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
36. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
38. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of hemoglobin levels in patients with primary epithelial ovarian carcinoma undergoing platinum-based chemotherapy.
Pongsanon K; Benjapibal M; Ruengkhachorn I
Asian Pac J Cancer Prev; 2011; 12(1):131-6. PubMed ID: 21517245
[TBL] [Abstract][Full Text] [Related]
40. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
